Rosen Law Firm Files Class Action Against Park Ha Biological Over Alleged Stock Manipulation — The Rosen Law Firm, P.A.

Event summary

Rosen Law Firm filed a class action lawsuit on behalf of Park Ha Biological Technology (NASDAQ: PHH, BYAH) stockholders who purchased securities between December 27, 2024, and July 8, 2025.
The lawsuit alleges Park Ha misled investors about its business operations, including a fraudulent stock promotion scheme involving social media-based misinformation.
Defendants are accused of omitting key risks related to false rumors and artificial trading activity driving the stock price.
Park Ha's IPO is claimed to have been structured with an extremely low public float to enable manipulation.

The big picture

This lawsuit highlights growing concerns over market manipulation in the biotech sector, particularly through social media-driven misinformation. The case underscores the need for stricter oversight of IPO structures to prevent artificial trading activity. Park Ha's situation may serve as a cautionary tale for other companies with similar financial engineering tactics.

What we're watching

Regulatory Scrutiny: How increased regulatory scrutiny of biotech IPOs will impact similar companies with low public floats.
Investor Confidence: Whether Park Ha can regain investor confidence amid allegations of stock manipulation.
Legal Precedent: The pace at which similar cases are resolved and their impact on future securities litigation.